Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.56
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.56
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)981.54K
Market Cap
$347.19M
Enterprise Value$70.67M
Total Cash (Recent Filing)$172.83M
Total Debt (Recent Filing)$3.82M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding64,652,920
10 Day Avg. Volume809,952
30 Day Avg. Volume981,541
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-89.37
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$17.00Price Target Upside205.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Discovery PlatformA proprietary computational biology and AI-driven platform provides a durable competitive advantage by improving target identification, speeding candidate design, and enabling repeated application across programs. This structural capability can lower cycle times, increase hit rates, and attract partners over multiple years.
Positive Phase 2a Pancreatic DataRobust 12-month OS (64% vs ~35% SOC) and no new safety signals materially de-risk the lead program and support a transition toward registrational activity. Plans for a pivotal Phase 3 and additional 2026 readouts create a clear multi-quarter regulatory and clinical pathway with lasting impact on commercial prospects.
Low LeverageVery low debt levels provide financial flexibility for a cash-burning biotech, reducing near-term insolvency risk and preserving optionality for executing clinical programs. Low leverage also improves strategic choices for funding (equity, partnerships) without immediate covenant pressure.
Bears Say
Sustained Negative Free Cash FlowMaterial and persistent negative operating and free cash flow driven by R&D spending creates a structural financing requirement. Continued cash burn implies recurring capital raises, which can dilute shareholders, constrain long-term planning, and risk program continuity if markets or partners pull back.
Pre-revenue, Persistent LossesLack of recurring revenue and sustained large losses mean the company's fundamental value hinges on successful clinical outcomes or partnerships. Without operating income, margin sustainability is absent and long-term viability depends on capital markets or milestone-based partner funding rather than internal cash generation.
Equity Volatility And Dilution RiskHistorical equity volatility and episodes of negative equity signal reliance on external financing and past dilution. This structural pattern raises the probability of future dilutive funding rounds, which can compress existing shareholder value and complicate long-term ownership and incentive alignment.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $347.19M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is May 12, 2026 which is in 7 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Mar 06, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.312 by $0.132.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.25.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,652,920 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.312. Following the earnings report the stock price went up 7.028%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (205.76% Upside)
$17.00 (205.76% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
337.79%
12-Months-Change
Fundamentals
Return on Equity
-43.33%
Trailing 12-Months
Asset Growth
340.08%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$17.00
▲(205.76% Upside)
Technical Analysis
Ownership Overview
9.48% Insiders
15.67% Mutual Funds
0.19% Other Institutional Investors
70.17% Public Companies and
Individual Investors